- Home
- TMQ vs EDIT Comparison
TMQ vs EDIT Comparison
Compare TMQ & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- EDIT
- Stock Information
- Founded
- TMQ 2004
- EDIT 2013
- Country
- TMQ Canada
- EDIT United States
- Employees
- TMQ N/A
- EDIT N/A
- Industry
- TMQ Precious Metals
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMQ Basic Materials
- EDIT Health Care
- Exchange
- TMQ Nasdaq
- EDIT Nasdaq
- Market Cap
- TMQ 249.6M
- EDIT 241.9M
- IPO Year
- TMQ N/A
- EDIT 2016
- Fundamental
- Price
- TMQ $2.08
- EDIT $2.71
- Analyst Decision
- TMQ
- EDIT Buy
- Analyst Count
- TMQ 0
- EDIT 12
- Target Price
- TMQ N/A
- EDIT $5.40
- AVG Volume (30 Days)
- TMQ 526.6K
- EDIT 1.2M
- Earning Date
- TMQ 10-07-2025
- EDIT 11-03-2025
- Dividend Yield
- TMQ N/A
- EDIT N/A
- EPS Growth
- TMQ N/A
- EDIT N/A
- EPS
- TMQ N/A
- EDIT N/A
- Revenue
- TMQ N/A
- EDIT $38,901,000.00
- Revenue This Year
- TMQ N/A
- EDIT N/A
- Revenue Next Year
- TMQ N/A
- EDIT N/A
- P/E Ratio
- TMQ N/A
- EDIT N/A
- Revenue Growth
- TMQ N/A
- EDIT N/A
- 52 Week Low
- TMQ $0.47
- EDIT $0.91
- 52 Week High
- TMQ $2.19
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- TMQ 65.90
- EDIT 51.66
- Support Level
- TMQ $1.78
- EDIT N/A
- Resistance Level
- TMQ $2.19
- EDIT $2.84
- Average True Range (ATR)
- TMQ 0.13
- EDIT 0.16
- MACD
- TMQ 0.04
- EDIT -0.09
- Stochastic Oscillator
- TMQ 80.95
- EDIT 94.54
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.